Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim and Hydra Biosciences agree new alliance

Boehringer Ingelheim and Hydra Biosciences agree new alliance

28th April 2014

Boehringer Ingelheim has announced a new drug research collaboration with Hydra Biosciences, a leader in the field of transient receptor potential (TRP) channel modulation.

The worldwide partnership will focus on researching and developing small-molecule TRPC4/5 inhibitors for the treatment of central nervous system diseases and disorders, leveraging the expertise and capabilities of both companies.

They will work together to identify and advance candidate inhibitors, with Boehringer Ingelheim handling global product development and commercialisation and Hydra receiving research funding and royalty payments to lead the scientific studies.

It is hoped that this collaboration will lead to the creation of new treatments that offer meaningful therapeutic improvements for CNS disorder patients.

Bernd Sommer, vice-president of neuroscience research at Boehringer Ingelheim, said: "We are very excited to collaborate with Hydra Biosciences and to be able to build on their significant expertise in the field of TRP channels."

The firm is currently working on around 90 research and development projects and is planning more than ten new product launches spanning eight indications in the next two years.ADNFCR-8000103-ID-801715533-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.